Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara(National Cancer Center Hospital East), Yung‐Jue Bang(Seoul National University), Josep Tabernero(Deaconess Hospital), Chie‐Schin Shih(St Nicholas Hospital), Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Hiroshi Yabusaki(Niigata Cancer Center Hospital), Sun Young Rha(Yonsei University), Nina Karaseva, S. G. Afanasyev(Research Institute of Medical Genetics of Russian Academy of Medical Sciences), Takaki Yoshikawa(Tokyo National Hospital), Patricio Yañez(Universidad de La Frontera), Sara Lonardi(Istituto Oncologico Veneto), M. A. Osipov(Leningrad Regional Cancer Center), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Do‐Youn Oh(Seoul National University Hospital), Hisateru Yasui(Kobe City Medical Center General Hospital), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jianming Xu(Chinese PLA General Hospital), Xiao Fang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Takashi Oshima(Kanagawa Prefectural Hospital Organization), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Salah-Eddin Al-Batran(Goethe University Frankfurt), Young Kyu Park(Chonnam National University Hwasun Hospital)
The Lancet Oncology
December 19, 2023
Cited by 336


Related Papers